Regeneron Pharmaceuticals (REGN) Announces Quarterly Earnings, Beats Expectations By $0.17 EPS
Regeneron Pharmaceuticals (NASDAQ:REGN) announced its earnings results on Tuesday. The company reported $2.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.30 by $0.17, American Banking News reports. The company had revenue of $666.00 million for the quarter, compared to the consensus estimate of $647.99 million. During the same quarter in the previous year, the company posted $1.73 earnings per share. The company’s revenue for the quarter was up 45.4% on a year-over-year basis.
A number of analysts have recently weighed in on REGN shares. Analysts at Roth Capital raised their price target on shares of Regeneron Pharmaceuticals from $382.00 to $399.00 in a research note on Wednesday, July 30th. On the ratings front, analysts at Argus initiated coverage on shares of Regeneron Pharmaceuticals in a research note on Monday, July 21st. They set a “buy” rating and a $375.00 price target on the stock. Five research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. Regeneron Pharmaceuticals presently has an average rating of “Buy” and an average target price of $346.00.
Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) traded up 2.02% on Tuesday, hitting $332.01. 501,357 shares of the company’s stock traded hands. Regeneron Pharmaceuticals has a 52 week low of $227.64 and a 52 week high of $352.49. The stock has a 50-day moving average of $303. and a 200-day moving average of $305.5. The company has a market cap of $32.772 billion and a P/E ratio of 93.30.
Regeneron Pharmaceuticals, Inc (NASDAQ:REGN) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.